证券代码：688389 证券简称：普门科技 公告编号：2024-080 深圳普门科技股份有限公司 关于 2024 年股票期权激励计划授予登记完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据 2024 年 9 月 26 日召开的深圳普门科技股份有限公司（以下简称"公司" 或"普门科技"）2024 年第一次临时股东大会的授权，公司于 2024 年 9 月 26 日召开第三届董事会第十一次会议、第三届监事会第十次会议，审议通过了《关 于向激励对象授予股票期权的议案》。根据中国证监会《上市公司股权激励管理 办法》以及上海证券交易所、中国证券登记结算有限责任公司上海分公司有关规 定，公司完成了 2024 年股票期权激励计划（以下简称"本激励计划"）的授予 登记工作，现将有关情况公告如下： 一、本激励计划已履行的相关审批程序 1、2024 年 9 月 9 日，公司召开了第三届董事会第十次会议，审议通过了《关 于〈公司 2024 年股票期权激励计划（草案）〉及其摘要的议案》《关于〈公司 2024 年股票期权激 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights that Pumen Technology (688389.SH) has shown strong performance in its overseas and IVD (in vitro diagnostics) business, with a net profit margin improvement [1] - The company reported a revenue of 857 million yuan for the first three quarters of 2024, representing a year-over-year increase of 5.89%, and a net profit of 257 million yuan, up 25.62% year-over-year [4] - The international business has seen significant growth, with a year-over-year revenue increase of 19.11% in the first three quarters, while the domestic revenue grew by 1.19% [4] - The IVD segment has performed particularly well, with domestic revenue growth of 15.17% and international revenue growth of 25.74% [4] - The company has maintained strong profitability, with a gross margin of 69.89% and a net profit margin of 29.89% for the first three quarters of 2024 [4] Financial Performance Summary - The company achieved a revenue of 2.67 billion yuan in Q3 2024, a year-over-year increase of 6.45%, and a net profit of 860 million yuan, up 21.51% year-over-year [4] - The projected revenues for 2024-2026 are 1.294 billion yuan, 1.498 billion yuan, and 1.736 billion yuan, respectively, with corresponding net profits of 406 million yuan, 484 million yuan, and 580 million yuan [5][6] - The company’s gross margin is expected to improve from 68.4% in 2024 to 69.8% in 2026, while the net profit margin is projected to increase from 31.3% to 33.3% over the same period [8] Growth and Development - The company has launched its fourth consecutive stock incentive plan, indicating confidence in long-term growth, with revenue and net profit growth targets set at 23% and 19% for 2024-2026, respectively [5] - The report emphasizes the company's commitment to R&D innovation and product line expansion, particularly in the chemical luminescence and rehabilitation sectors, which are expected to drive continued growth [5]

Investment Rating - The report maintains a "Recommend" rating for Pumen Technology with a target price of 21 CNY, compared to the current price of 17.23 CNY [1] Core Views - Pumen Technology's Q3 2024 performance met expectations, with IVD (In Vitro Diagnostics) business maintaining rapid growth [1] - The company's international business continues to grow at a high rate, with international market revenue reaching 253 million CNY (+19.11%) in Q1-Q3 2024, accounting for 29.5% of total revenue [2] - IVD business shows strong growth both domestically and internationally, with domestic IVD revenue at 442 million CNY (+15.17%) and international IVD revenue at 237 million CNY (+25.74%) in Q1-Q3 2024 [2] - The company's profitability has improved, with Q3 2024 gross margin reaching 70.07% (+0.98pct) and net profit margin at 32.05% (+3.97pct) [2] - A new incentive plan was released in September 2024, demonstrating confidence in future growth, with performance targets of 23%, 46%, and 69% revenue or net profit growth for 2024-2026 compared to 2023 [2] Financial Performance - Q1-Q3 2024 revenue reached 857 million CNY (+5.89%), with net profit attributable to shareholders of 257 million CNY (+25.62%) [1] - Q3 2024 revenue was 267 million CNY (+6.45%), with net profit attributable to shareholders of 86 million CNY (+21.51%) [1] - The company's 2024-2026 net profit is forecasted to be 410 million, 490 million, and 590 million CNY, representing growth rates of 23.8%, 19.9%, and 20.5% respectively [2] - EPS for 2024-2026 is projected to be 0.95, 1.14, and 1.37 CNY, with corresponding P/E ratios of 18, 15, and 13 times [2] Business Development - The company has established subsidiaries in Russia and Indonesia to enhance localized marketing capabilities [2] - Pumen Technology has launched innovative products, including a new generation 25-hydroxyvitamin D assay kit using small molecule sandwich technology and the LifoLas 8000 and LifoLas 9000 automated immunoassay systems [2] Financial Projections - Revenue for 2024-2026 is projected to be 1.245 billion, 1.438 billion, and 1.721 billion CNY, with growth rates of 8.7%, 15.5%, and 19.7% respectively [3] - Gross margin is expected to improve from 65.8% in 2023 to 71.5% in 2026 [6] - ROE is forecasted to increase from 18.3% in 2023 to 20.5% in 2026 [6]

北京市中伦（深圳）律师事务所 关于深圳普门科技股份有限公司 2021 年及 2023 年股票期权激励计划相关事项的 法律意见书 二〇二四年十月 北京市中伦（深圳）律师事务所 关于深圳普门科技股份有限公司 2021 年及 2023 年股票期权激励计划相关事项的 法律意见书 5．本所及本所律师同意公司在其为实行本次注销及行权事项所制作的文件中 引用本法律意见书的相关内容，但公司作上述引用时，不得因引用而导致法律上 的歧义或曲解，本所有权对上述相关文件的相应内容再次审阅并确认。 致：深圳普门科技股份有限公司 北京市中伦（深圳）律师事务所接受深圳普门科技股份有限公司（以下简称 "普门科技"或"公司"）的委托，担任普门科技实施 2021 年股票期权激励计划、 2023 年股票期权激励计划相关事宜的专项法律顾问。本所律师根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、中国证券监督管理委员会（以下简称"中国证监会"） 发布的《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海 证券交易所科创板股票上市规则》等有关法律、法规、规范性文件和《深圳普门 ...

证券代码：688389 证券简称：普门科技 公告编号：2024-079 深圳普门科技股份有限公司 关于2023年股票期权激励计划第一个行权期 自主行权实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●股票期权拟行权数量：210.00万份； ●行权股票来源：公司向激励对象定向发行公司A股普通股股票； ●行权安排：本次股票期权行权期限自自主行权审批手续办理完毕之日始至 2025年9月11日止（根据手续办理情况，实际可行权期限为2024年11月8日至2025 年9月11日止，行权日须为交易日）。 一、股权激励计划批准及实施情况 （一）股票期权激励计划方案及履行程序 公司于 2023 年 8 月制定并实施了《深圳普门科技股份有限公司 2023 年股票 期权激励计划（草案）》，合计向激励对象授予 809.00 万份股票期权，行权价 格为 21.00 元/份，有效期为自股票期权授予之日起至激励对象获授的股票期权全 部行权或注销完毕之日止，最长不超过 60 个月。 2023 年 8 月 23 日，公司召开了第二 ...

深圳普门科技股份有限公司 监事会对第三届监事会第十一次会议相关事项 的核查意见 规和规范性文件的有关规定。 综上所述，监事会同意公司注销 2021 年股票期权激励计划首次授予部分股 票期权合计 3,532,115 份，同意注销 2023 年股票期权激励计划部分股票期权合计 1,090,000 份；同意符合 2021 年股票期权激励计划首次授予股票期权第三个行权 期行权条件的 220 名激励对象在规定的行权期内采取自主行权的方式行权；同意 符合 2023 年股票期权激励计划第一个行权期行权条件的 165 名激励对象在规定 的行权期内采取自主行权的方式行权。 深圳普门科技股份有限公司监事会 2024 年 10 月 14 日 （以下无正文） 深圳普门科技股份有限公司（以下简称"公司"）监事会依据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》《上海证 券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权 激励信息披露》等相关法律、法规和规范性文件以及《公司章程》等有关规定， 对公司第三届监事会第十一次会议的相关事项进行审核，发表核查意见如下： 一、公司本次因 23 ...

证券代码：688389 证券简称：普门科技 公告编号：2024-078 深圳普门科技股份有限公司 关于2021年股票期权激励计划首次授予股票期权 第三个行权期自主行权实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●股票期权拟行权数量：419.80万份； ●行权股票来源：公司向激励对象定向发行公司A股普通股股票； ●行权安排：本次股票期权行权期限自自主行权审批手续办理完毕之日始至 2025年10月10日止（根据手续办理情况，实际可行权期限为2024年11月8日至2025 年10月10日止，行权日须为交易日）。 一、股权激励计划批准及实施情况 （一）股票期权激励计划方案及履行程序 公司于2021年9月制定并实施了《深圳普门科技股份有限公司2021年股票期 权激励计划（草案）》，合计向激励对象授予1,600.00万份股票期权。其中首次 授予部分合计向334名激励对象授予1,438.00万份股票期权，行权价格为每股 21.00元，有效期为自股票期权授予之日起至激励对象获授的股票期权全部行权 或注销完毕之 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][3]. Core Views - The IVD production line is experiencing steady growth, with rapid expansion in international markets. Clinical medical and dermatology aesthetics businesses are under short-term pressure but are expected to gradually recover [2]. - The target price has been raised to 21.85 CNY, reflecting an increase from the previous forecast of 19.20 CNY [3]. Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 857 million CNY, representing a year-on-year increase of 5.89%. The net profit attributable to shareholders was 257 million CNY, up 25.62%, and the net profit excluding non-recurring items was 243 million CNY, up 29.11% [8]. - The gross margin for Q1-Q3 was 69.89%, an increase of 3.48 percentage points, while the net profit margin was 29.89%, up 4.65 percentage points [8]. Business Segment Analysis - The IVD business generated revenue of 678 million CNY, a growth of 19%, with domestic revenue at 442 million CNY (up 15%) and international revenue at 237 million CNY (up 26%) [8]. - The clinical medical and dermatology aesthetics segments are currently facing challenges due to a high base in 2023 and a slowdown in hospital bidding processes. However, there is potential for recovery as the industry bidding resumes [8]. Financial Forecasts - The report has adjusted the EPS forecasts for 2024-2026 to 0.95 CNY, 1.14 CNY, and 1.37 CNY respectively, down from previous estimates of 0.96 CNY, 1.20 CNY, and 1.51 CNY [8]. - The company is expected to maintain a net profit growth rate of approximately 20% in the coming years, with projected net profits of 405 million CNY in 2024, 487 million CNY in 2025, and 586 million CNY in 2026 [9].

证券代码：688389 证券简称：普门科技 编号：2024-016 深圳普门科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------------|----------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 (电话会议 ) | | | 参与单位及人员 | 共 105 家机构， 142 | 位参与人员 | | 时间 | 2024 年 10 月 29 日、 30 | 日 | | 地点 | 线上电话会议 | | | | 总经理：胡明龙 | | | 上市公司接待人 | 副总经理：李大巍 | | | 员姓名 | 副总经理：邱亮 | | | | 财务总监：王红 | | | | 董事会秘书：路曼 | | | | 公司披露 2024 流内容如下： | 年第三季度报告 ...

Financial Performance - The company's operating revenue for the first three quarters of 2024 reached 857 million yuan, representing a year-on-year growth of 5.89%[20] - The net profit attributable to shareholders for the same period was 257 million yuan, with a year-on-year increase of 25.62%[20] - In Q3 2024, the operating revenue was 267 million yuan, showing a year-on-year growth of 6.45%[21] - The gross profit margin stood at 69.89%, while the net profit margin was 29.89%[12][14] - The net cash flow from operating activities increased by 42.78% year-on-year, reaching 253 million yuan[29] Research and Development - R&D investment for the first three quarters of 2024 amounted to 152 million yuan, reflecting a year-on-year increase of 9.51%, which is 17.73% of operating revenue[26] - The company has obtained a total of 218 valid patents, including 55 invention patents, as of September 30, 2024[26] - The company launched a new generation of double antibody sandwich 25-hydroxyvitamin D assay kit and a bronchoscopic visual soft mirror, marking significant advancements in product development[26] Expansion and Incentives - The company established a subsidiary in Russia in July 2024, enhancing its global presence[27] - The company plans to grant 11.31 million stock options to 186 key personnel as part of its 2024 stock option incentive plan[28]